Announcements Trials

Browse Landscape

Phase

Status

Completed 8 Unknown 2 Withdrawn 1 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 6 Leukemia, Myeloid, Acute 4 Thyroid Neoplasms 2 Neoplasms 2 Hepatoblastoma 2 Thyroid cancer, Hurthle cell 1 Thyroid Diseases 1 Squamous Cell Carcinoma of Head and Neck 1 Rhabdomyosarcoma 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Melanoma 1 Gastrointestinal Stromal Tumors 1 Fibrolamellar hepatocellular carcinoma 1 Desmoplastic Small Round Cell Tumor 1 Carcinoma 1

Interventions

Dexamethasone 18 Cyclophosphamide 16 fludarabine 11 pomalidomide 9 pembrolizumab 9 carfilzomib 9 daratumumab 7 Rituximab 7 Lenalidomide 7 Calcium Dobesilate 7 fludarabine phosphate 6 Gemcitabine 6 Cisplatin 6 Bortezomib 6 venetoclax 5 elotuzumab 4 isatuximab 3 blinatumomab 3 Vincristine 3 Radiotherapy 3 Prednisone 3 Etoposide 3 Doxorubicin 3 Cytarabine 3 tisagenlecleucel 2 selinexor 2 ruxolitinib 2 ixazomib 2 dexamethasone 21-phosphate 2 cabazitaxel 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Recurrence × Sorafenib × Clear all

NCT02298348 2026-03-23

N2013-02

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Active not recruiting

Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡